6 research outputs found
Low Dose ATG-Fresenius Might be Effective in the Prophylaxis of Severe Graft Versus Host Disease with Low Non-Relapse Mortality
No full textDifferences of Antithymocyte Globulin (ATG) Side Effects during Allogeneic Stem Cell Transplantation
No full textLong-Term Follow up of Healthy Donors Receiving G-CSF for Peripheral Blood Progenitor Cell Mobilization and Collection.
No full textRisk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis
Get PDFDiffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease entity. Young patients with high-intermediate and high aa-IPI score seem to be good candidates to receive alternative treatments to standard RCHOP-21 including EPOCH-R,2 R-ACVBP+HDT-ASCT3 and upfront autologous stem cell transplantation. Other risk factors can be used to identify patients for the use of more doseintense regimens including bulky disease, interim PET positivity and, importantly, molecular profiles
